An "export-only" exception to pharmaceutical patents in Europe: Should the U.S. follow suit?

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

An "export-only" exception to pharmaceutical patents in Europe: Should the U.S. follow suit? / Minssen, Timo; Kesselheim, Aaron; Darrow, Jonathan.

In: Nature Biotechnology, Vol. 37, No. 1, 03.01.2019, p. 21-22.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Minssen, T, Kesselheim, A & Darrow, J 2019, 'An "export-only" exception to pharmaceutical patents in Europe: Should the U.S. follow suit?', Nature Biotechnology, vol. 37, no. 1, pp. 21-22. https://doi.org/10.1038/nbt.4324

APA

Minssen, T., Kesselheim, A., & Darrow, J. (2019). An "export-only" exception to pharmaceutical patents in Europe: Should the U.S. follow suit? Nature Biotechnology, 37(1), 21-22. https://doi.org/10.1038/nbt.4324

Vancouver

Minssen T, Kesselheim A, Darrow J. An "export-only" exception to pharmaceutical patents in Europe: Should the U.S. follow suit? Nature Biotechnology. 2019 Jan 3;37(1):21-22. https://doi.org/10.1038/nbt.4324

Author

Minssen, Timo ; Kesselheim, Aaron ; Darrow, Jonathan. / An "export-only" exception to pharmaceutical patents in Europe: Should the U.S. follow suit?. In: Nature Biotechnology. 2019 ; Vol. 37, No. 1. pp. 21-22.

Bibtex

@article{5713cb446f3643f79651738ad2a7c589,
title = "An {"}export-only{"} exception to pharmaceutical patents in Europe: Should the U.S. follow suit?",
abstract = "A new European Union policy could increase the supply of legitimate pharmaceuticals in developing countries and thereby minimize the problem of counterfeit medicines, but many challenges remain. This paper describes the proposed European legislation and discusses its' potential strengths, weaknesses, opportunities and threats. Ultimately, we consider if the United States should consider similar policies.",
author = "Timo Minssen and Aaron Kesselheim and Jonathan Darrow",
year = "2019",
month = "1",
day = "3",
doi = "https://doi.org/10.1038/nbt.4324",
language = "English",
volume = "37",
pages = "21--22",
journal = "Nature Biotechnology",
issn = "1087-0156",
publisher = "nature publishing group",
number = "1",

}

RIS

TY - JOUR

T1 - An "export-only" exception to pharmaceutical patents in Europe: Should the U.S. follow suit?

AU - Minssen, Timo

AU - Kesselheim, Aaron

AU - Darrow, Jonathan

PY - 2019/1/3

Y1 - 2019/1/3

N2 - A new European Union policy could increase the supply of legitimate pharmaceuticals in developing countries and thereby minimize the problem of counterfeit medicines, but many challenges remain. This paper describes the proposed European legislation and discusses its' potential strengths, weaknesses, opportunities and threats. Ultimately, we consider if the United States should consider similar policies.

AB - A new European Union policy could increase the supply of legitimate pharmaceuticals in developing countries and thereby minimize the problem of counterfeit medicines, but many challenges remain. This paper describes the proposed European legislation and discusses its' potential strengths, weaknesses, opportunities and threats. Ultimately, we consider if the United States should consider similar policies.

U2 - https://doi.org/10.1038/nbt.4324

DO - https://doi.org/10.1038/nbt.4324

M3 - Journal article

VL - 37

SP - 21

EP - 22

JO - Nature Biotechnology

JF - Nature Biotechnology

SN - 1087-0156

IS - 1

ER -

ID: 204531230